Razpis: Programme to Accelerate Clinical Trials (PACT)
Funding for biomarker-based, proof-of-concept pilot clinical trials relevant to Alzheimer's disease, other dementias and cognitive ageing.
Financer: Alzheimer's Drug Discovery Foundation
Vrednost projekta: 2.920.000,00 EUR
Upravičenost kandidatov: javne in zasebne pravne osebe, profitne in neprofitne organizacije, vključno z akademskimi ustanovami in biotehnološkimi podjetji, ne glede na lokacijo
Rok za prijavo: 17. 11. 2017
Prijava: preko spletne strani
Founded in 1998 by co-chairman Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation (ADDF) provides funding to leading scientists who are conducting the most promising, innovative Alzheimer's drug research worldwide.
The ADDF aims to plug the translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programmes relevant to Alzheimer's disease, other dementias and cognitive ageing.
The ADDF's Programme to Accelerate Clinical Trials (PACT) scheme is intended to increase the number of innovative drugs tested in humans at the proof of concept stage for Alzheimer's disease. This programme will fund biomarker-based, proof-of-concept pilot clinical trials for Alzheimer's through three mechanisms:
- Academic Programme: seeks to create and support innovative translational programmes in academic medical centres and universities.
- Biotechnology Development Programme: supports qualified scientific projects in existing, private, early stage biotechnology companies. The ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified. Funding is typically made as a programme-related investment.
- Biotechnology Founders Technology Transfer Programme: supports academic programmes that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35 % of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs.
Terms and Conditions
Programme areas of particular interest include:
- Repurposing: Testing drugs approved for other indications in Alzheimer's disease clinical trials. Proposals should be hypothesis driven and drugs chosen for testing should target a mechanism of action(s) common to both diseases.
- Therapies addresing the following targets: Energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury and the blood-brain barrier interface.